Trial · NCT04988217
Inhaled Interferon α2b for the Treatment of Coronavirus Disease 19 (COVID-19)
NCT04988217, Phase 1, Phase 2, Completed, Pontificia Universidad Catolica de Chile
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Inhaled Interferon α2b for the Treatment of Coronavirus Disease 19 (COVID-19). Trials, record NCT04988217. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04988217
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Inhaled Interferon α2b for the Treatment of Coronavirus Disease 19 (COVID-19)
- NCT number
- NCT04988217
- Status
- Completed
- Phases
- Phase 1, Phase 2
- Enrollment
- 173 participants, actual
- Lead sponsor
- Pontificia Universidad Catolica de Chile
- Conditions
- Coronavirus Disease 2019
- Interventions
- Interferon-Alpha2B, Placebo
- First posted
- 2021-08-03
- Last updated
- 2022-08-05
Source ClinicalTrials.gov
Registered outcomes17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Treatment-emergent adverse events in healthy subjects | At the end of Phase 1 (Phase 1 is 11 days) | Safety and tolerability of AP-003 as measured by subject incidence of treatment-emergent adverse events. |
| Primary | Change in perception of health status measured by EQ VAS in COVID-19 patients | At Day 5 of Phase 2 (Phase 2 is 28 days) | Changes from baseline evaluation in COVID-19(+) participants' perception of health status at Day 5 as measured by EQ VAS in AP-003 treated patients compared to placebo. |
| Secondary | Serum levels of interferon alpha 2b | Up to Day 11 of Phase 1 (Phase 1 is 11 days) | Pharmacokinetics of nebulized AP-003 in healthy adults assessed by serial serum quantification of interferon alpha 2b |
| Secondary | Expression of interferon-induced genes in blood sputum samples | Up to Day 11 of Phase 1 (Phase 1 is 11 days) | Evaluation of interferon-induced biomarkers after treatment with AP-003 in blood and sputum of healthy adults to assess biological effect of Interferon |
| Secondary | Change in perception of health status measured by EQ VAS | Day 10 of Phase 2 (Phase 2 is 28 days) | Changes in participants' perception of health status from baseline to Day 10 as measured by EQ VAS in AP-003 treated patients compared to placebo. |
| Secondary | Change in perception of health status measured by EQ VAS | Day 28 of Phase 2 (Phase 2 is 28 days) | Changes in participants' perception of health status from baseline to Day 28 as measured by EQ VAS in AP-003 treated patients compared to placebo. |
| Secondary | Change in EuroQoL Quality of Life instrument (EQ-5D-5L) | Up to day 28 of Phase 2 (Phase 2 is 28 days) | Changes in participants' perception of health status from baseline to Day 5, from baseline to Day 10, and from baseline to Day 28 as measured by EuroQoL Quality of Life instrument (EQ-5D-5L). |
| Secondary | Change in Ordinal Scale for Clinical Improvement | Up to day 28 of Phase 2 (Phase 2 is 28 days) | Changes in participants' overall health from baseline to Day 5, from baseline to Day 10, and from baseline to Day 28 as measured by Ordinal Scale for Clinical Improvement in AP-003 treated patients compared to placebo. |
| Secondary | Improvement in clinical symptoms | Up to day 28 of Phase 2 (Phase 2 is 28 days) | Changes in participant's improvement in clinical symptoms from baseline to Day 5, from baseline to Day 10, and from baseline to Day 28 as measured by a daily symptom diary in AP-003 treated patients compared to placebo. |
| Secondary | Emergency department visits | Up to day 28 of Phase 2 (Phase 2 is 28 days) | The proportion of participants attending an emergency department for COVID-19 by Day 28 in AP-003 treated patients compared to placebo. |
1 to 10 of 17Source ClinicalTrials.gov
See all 17 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 37347370 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04988217
GET https://conductscience.org/api/trials/v1/NCT04988217/registered